Accelerated LVV Manufacturing Enabled By Platform Excellence

A leading biotechnology company faced a major setback when their lentiviral vector (LVV) supplier announced they couldn't deliver the critical component needed for an upcoming clinical trial. With only eight months until the LVV was required for clinical manufacturing, the risk of jeopardizing key milestones and triggering significant financial consequences was high.

To overcome this critical supply shortfall, the company urgently needed a manufacturing partner who could meet rigorous quality standards on a compressed schedule. This case study details how SK pharmteco leveraged the maturity of its LentiSure™ platform, along with a well-rounded strategy combining early material readiness, streamlined documentation, and in-house analytical testing, to execute a 50 L suspension process. The integrated and efficient execution delivered the final LVV product within the accelerated eight-month timeframe , avoiding costly delays and maintaining the customer’s momentum toward market-entry milestones.

Discover how a flexible, robust manufacturing platform can compress a typical year-long timeline to just eight months, demonstrating the power of agility and preparedness in overcoming urgent supply challenges.